Table 4 Adjusted hazard ratios (95% confidence intervals) of selected outcomes comparing new rivaroxaban users to new dabigatran users for the treatment of non-valvular atrial fibrillation, MarketScan, 2010–2014
|  | Rivaroxaban User (n = 16,957) | Matched Dabigatran User (n = 16,957) | Hazard Ratio (95% CI) a | p-value | ||||
|---|---|---|---|---|---|---|---|---|
Main outcomes | # Events | Person-years | IR (95% CI) | # Events | Person-years | IR (95% CI) | Â | Â |
 Ischemic stroke | 82 | 21,721 | 3.8 (3.0–4.7) | 107 | 21,723 | 4.9 (4.1–5.9) | 0.77 (0.58–1.03) | 0.08 |
 Intracranial bleeding | 26 | 21,787 | 1.2 (0.8–1.7) | 17 | 21,774 | 0.8 (0.5–1.2) | 1.47 (0.80–2.72) | 0.22 |
 Myocardial infarction | 140 | 21,734 | 6.4 (5.4–7.6) | 124 | 21,703 | 5.7 (4.8–6.8) | 1.11 (0.87–1.41) | 0.42 |
 Gastrointestinal bleeding | 255 | 21,633 | 11.8 (10.4–13.3) | 198 | 21,641 | 9.1 (7.9–10.5) | 1.28 (1.06–1.54) | 0.01 |
Control outcomes | ||||||||
 Hip / pelvic fracture | 101 | 21,770 | 4.6 (3.8–5.6) | 116 | 21,706 | 5.3 (4.4–6.4) | 0.88 (0.67–1.15) | 0.34 |
 Breast / prostate cancer | 140 | 21,726 | 6.4 (5.4–7.6) | 130 | 21,719 | 6.0 (5.0–7.1) | 1.06 (0.84–1.35) | 0.61 |
 Asthma | 245 | 21,645 | 11.3 (10.0–12.8) | 203 | 21,629 | 9.4 (8.2–10.7) | 1.18 (0.98–1.42) | 0.09 |